Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine Dose Ranging vs Efavirenz in HIV-1
NCT01632345Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2012
- Primary completion
- Dec 2014
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of doravirine in human immunodeficiency virus type 1 infection (HIV-1) (5 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With CNS Events at 24 weeks, Percentage of Participants With At Least 1 AE at 96 weeks and 2 more. Started Oct 2012; status: completed.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01632345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01632345.